Allergic bronchopulmonary aspergillosis.
Allergic bronchopulmonary aspergillosis (ABPA) occurs in nonimmunocompromised patients and belongs to the hypersensitivity disorders induced by Aspergillus. Genetic factors and activation of bronchial epithelial cells in asthma or cystic fibrosis are responsible for the development of a CD(4)+Th2 lymphocyte activation and IgE, IgG and IgA-AF antibodies production. The diagnosis of ABPA is based on the presence of a combination of clinical, biological and radiological criteria. The severity of the disease is related to corticosteroid-dependant asthma or/and diffuse bronchiectasis with fibrosis. The treatment is based on oral corticosteroids for 6-8 weeks at acute phase or exacerbation and itraconazole is now recommended and validated at a dose of 200 mg/day for a duration of 16 weeks.
Tillie-Leblond
I
I
Department of Pulmonology and Immuno-Allergology, University Hospital of Lille, Lille, France.
Tonnel
A-B
AB
D001229:Aspergillosis, Allergic Bronchopulmonary / Q000175:diagnosis / Q000382:microbiology / Q000503:physiopathology / Q000628:therapy; D001232:Aspergillus fumigatus / Q000502:physiology; D006801:Humans